Back pain is the second most common reason for primary-care physician visits after the common cold. New understanding of the spine pathophysiology and biomechanics led to the development of novel injectable biomaterials to treat those pain generators. Although not all biomaterials are currently ready for common use, there is significant interest by the medical community to invest time, resources, and energy to optimize these injectables. This review introduces basic concepts and advancements in the field of bioinjectables tailored for the vertebral body. Also, we highlight advances in injectable biomaterials which were presented at the Groupe de Recherche Interdisciplinaire sur les Biomat eriaux Ost eoarticulaires Injectables (GRIBOI) (Interdisciplinary Research Society for Injectable Osteoarticular Biomaterials) meeting in March 2018 in Los Angeles, CA. Indeed, multidisciplinary translational research and international meetings such as GRIBOI bring together scientists and clinicians with different backgrounds/expertise to discuss injectable biomaterials innovations tailored for the interventional pain management field.
Low back pain is the largest contributor to Years Lived with Disability according to the most recent Global Burden of Disease Study [1] . This condition is extremely costly for our society, with estimated costs of $100 billion spent each year in the United States. A significant proportion of spine pain generators arise from the anterior column and are related either to degenerative disc disease, endplate degenerative changes, or vertebral compression fractures (VCFs).
Of all these pain generators, VCFs have the most negative impact on patient's pain, function, and quality of life, while being extremely prevalent in our population (affect w25% of people over 50 years old) [2] . Most of these fractures are related to osteoporosis, although other etiologies, such as neoplasm, trauma, or underlying infection, may predispose to fractures. Indeed, the most important potentially modifiable risk factor for VCFs is the presence of osteoporosis, but other risks factors should include being of Caucasian or Northern European descent, female sex, advanced age, susceptibility to fall, presence of dementia, and history of fractures in a first-degree relative [3] .
Nonsurgical management, such as bracing and pain management medication, is unproven in regards to efficacy and does not provide adequate long-term pain control while increasing the mortality and morbidity risks of patients secondary to higher risks of cardiac complications and pneumonia [3, 4] . On the other hand, surgical instrumentation has limited utility since the fixation does not provide sufficient mechanical stability of the fracture cleft, which results in residual pain. Also, patients with osteoporotic VCFs are at risk of pedicle screw loosening due to reduced quality and amount of bone.
VCFs can be treated with minimally invasive interventions, including percutaneous vertebroplasty and kyphoplasty [5, 6] . In these procedures, needle punctures are made, and the needles are placed within the vertebral bodies followed by injection of cement or other biomaterials through the cannula while monitoring the material via X-ray fluoroscopy. When kyphoplasty is performed, prior to injecting cement, an inflatable bone tamp or other mechanical device is inserted into a fractured vertebral body to restore the height of vertebral body and to create a cavity within the cancellous bone, and then the vertebral body is filled with the injectable material. Overall, kyphoplasty has increased the quality of life for patients, rapidly decreased the pain, increased the height of vertebral bodies, and provided additional restoration of the kyphotic angle ( Figure 1 ) [6] . The goal of the intervention is to fill the fracture cleft while providing mechanical support to the vertebral body to decrease pain and the possibility of refracture ( Figure 2 ). Injectable cements remain the most important building material for the treatment of painful VCFs. Acrylic-based cements were the first type of cement used to treat fractures in the 1980s. Indeed, the first use of acrylic based cementdpolymethylmethacrylate (PMMA)din the spine was performed by Galibert et al in 1987 as a way to stabilize a vertebral hemangioma [7] .
The non-degradability of the PMMA cement and the differences in the biomechanical characteristics of the PMMA and the surrounding cancellous bone [8] of the treated vertebral bodies led some investigators to believe that the instillation of PMMA may result in an increased rate of adjacent VCFs. However, a meta-analysis performed by Papanastassiou et al demonstrated the opposite with a significant decrease of adjacent level fracture after augmentation [9] . Ongoing discussions about the risk of adjacent level fractures, however, led the industry and researchers to develop new tools or cements with different mechanical characteristics. Since then, injectable bone cements, osteoconductive ceramic biomaterials, and hydrogels have been used effectively and have gained popularity. Important advancements, highlights, and new technologies presented at the GRIBOI 2018 meeting are discussed and reviewed below.
Advances in Injectable Therapeutics

Cements Polymethylmethacrylate
Although other types of cements exists, currently the only type of cement approved in the US is acrylic based cement such as PMMA. This type of cement is composed of solid and liquid phases. The solid phase is composed of prepolymerized PMMA polymer powder that includes a catalyst (benzyl peroxide) and selected radio-opacification agents such as barium sulfate, zirconium dioxide, tantalum, and/or tungsten. The liquid phase is composed of methylmethacrylate monomers that contains an activator (most frequently N, N-dimethyl-p-toluidine). When the solid and liquid phases of the acrylic-based cement are mixed, heat is released during the curing process in addition to the increase in cement viscosity.
During this process, the cement passes through different important phases. First, from the moment the solid and liquid phases are mixed up until the moment the cement does not stick to the glove is called the ''Dough Time'' (typically in the first 3 minutes of the curing process). This period is followed by the ''Working Time,'' the period when the cement is of adequate consistency to be manipulated and injected without being too viscous to exert control on the injection forces (typically less than 15 minutes). A third period described is called the ''Setting Time,'' which starts at the end of the mixing and lasts up until the exothermic reaction temperature at the surface of the cement reaches 50% of its maximum value (this is typically about 8 minutes).
In the last few years, mechanical characteristics such as porosity and biodegradability of acrylic-based cements have been improved. Porosity of the cement is an important physical characteristic to allow osteoconductivity (growth of new cancellous bone into the cement). Finding the balance between the degrees of porosity of the cement that will allow new bone ingrowth but which weakens the cement has been of recent interest. For instance, cements with biodegradable fillers give the potential to grow new bone while providing initial mechanical stability to consolidate the fracture and decrease the patient's pain [10] .
The exothermic reaction during the polymerization process of PMMA and cardiopulmonary toxicity of the unreacted monomer can give rise to some concerns. In regard to the concern from excess heat produced from the PMMA hardening, studies by Deramond et al recorded temperatures of 50 C within the vertebral body and up to 41 C in the posterior edge, leading to the conclusion that spinal-cord damage by polymerization heat does not occur and that in their review of the literature, they found no reports of temperature damage to the vertebral bodies as a result of the heat of polymerization of cement used in vertebroplasty [11] . Lai et al also concluded that bone cement polymerization temperatures do not cause thermal injury to the surrounding soft tissues and, to our knowledge, there has been no adverse report of bone necrosis related to the curing of bone cement in patients undergoing kyphoplasty [12] or other orthopedic procedures in long bones, skull, pelvis, or spine after utilizing PMMA for decades. However, it remains unclear whether or not the in situ heat contributes to the release of bone marrow tissue into the circulatory system. The concern for hypotension related to the unreacted monomer is connected to cemented joint arthroplasties, and little data is available concerning potential cardiovascular effects in the percutaneous bone augmentation procedures. Kaufmann et al, however, a retrospective study showed a significant drop in the oxygen saturation 10 minutes after the cement injection [13] .
The concern over the release of cytotoxic monomers, inhibition of bone perfusion, and increased bone resorption are mainly related to placement of total joint arthroplasties, and not to vertebral augmentation. A review of all of the level I and II data shows that most studies did neither report nor encounter any serious adverse events (SAEs) with PMMA, and overall, the literature suggests that both procedures had safe SAE profiles with occasional case reports of symptomatic cement extravasation [14e21]. Furthermore, Aebli et al [22] have shown that pressurization during vertebroplasty in sheep significantly alters cardiovascular function with increasing the number of levels augmented, but both PMMA and liquid wax produced similar altered cardiovascular effects. Given these results, they concluded that the altered function was related to the in situ pressurization of the cement rather than a specific consequence of the PMMA monomer.
It is also known that there is leakage of bone marrow tissue into the vascular system during vertebral augmentation [23] . During the cement-injection process, the cement takes the space occupied by the bone marrow and displaces it, causing an increase in the embolic load to the patient [24] . Cement can also extravasate into the vascular system during the bone cement-injection process has been one of the most frequently reported and serious complications in the bone augmentation procedure [5, 7, 15] . Each of these leaks or extravasations represents a risk to the patient (ie, pulmonary embolism, intracardiac cement or fat embolism, embolic stroke, and possible death) [25] . In mechanical terms, these two different types of extravasation, that is, cement and bone marrow result from the uncontrolled in situ pressure and flow conditions, which can be controlled by a slight suction [26, 27] .
Substantial efforts have been made to exert greater control on conditions which lead to extravasations. In this regard, most early clinical research aimed at reducing the risk of leakage focused on visualization techniques to detect extravasation [25] . Currently, medical cements used for percutaneous purposes contain a large percentage of radiopaque agents for better visualization.
Reilly et al shifted the paradigm by focusing on the preparation of bone to receive the cement filling [28] . This procedure known as kyphoplasty became popular and is now performed more commonly than vertebroplasty. Bohner and Baroud studied the force and flow affecting extravasation in a structured manner and found that the use of highly thick cement is the most practical solution for controlling the intervertebral filling patterns and cement extravasations [29, 30] . Currently, PMMA quick to dough cement that immediately thickens once mixed, is marketed by almost every manufacturer in the field, together with mechanically leveraged injection devices to manage the high injection pressure.
Mohme et al voiced concerns over the risk of increased dissemination of tumour cells into the vascular system, with particularly high rates in vertebral metastatic patients purportedly because of the elevated intra-metastatic pressure during bone augmentation procedures [31] . The authors claimed that the bone augmentation procedure led to the mechanical displacement of tumour cells into the vascular system and that those cells spread to other organs. This phenomenon supports the argument for the potential benefits of removing tumour cells before augmentation with an ablation device [32] .
Despite the potential for tumour spread, the survival of patients undergoing vertebral augmentation in the face of cancer is prolonged by the bone augmentation procedure itself [33] and whether or not new distant metastases are truly caused by the displaced tumour cells or whether these new sites are the results of parallel development of previously existing micro-metastases remains unclear.
Calcium phosphate
Calcium phosphate (CP) powder is added to aqueous solution to produce an injectable viscous cement paste. CP cements are characterized by improvement in osteoconductivity, biodegradability, and a nonexothermic reaction. However, they have relatively poor mechanical properties in comparison to PMMA. Mixed PMMA-CP cements are currently available in the US and help keep some of the advantages of both cement types. Also, adding certain compounds, such as protein, bioactive glass, and bioceramic, has been studied to improve the mechanical properties [34] . Promising results are seen with strontium substituted CP that might be able to promote bone formation and suppress bone resorptionda major problem associated with CP cements. A prospective non-randomized controlled study of 26 patients was performed to evaluate the performance of Callos CPC to treat osteoporotic VCFs with balloon kyphoplasty. The authors noticed a decreased VAS and Oswestry Disability Index scores to a similar degree as patients treated with PMMA but although vertebral height loss was reduced after intervention, a 32% recurrent progression of height loss was observed at the time of follow-up. Also, CP cement leakage in the spinal canal was observed in almost 50% of patients. Those results brought serious concern about the possible clinical use of this type of cement [35] .
Other biomaterials
Alternative biomaterials have been proposed for use in vertebral augmentation each with certain enhancements. These materials include carbonated apatite, bioactive PMMA, and combeite glass ceramics [36] . In a recent clinical study, short segment posterior instrumentation was combined with calcium sulfate cement (CSC) vertebroplasty for thoracolumbar compression fractures. Despite historic success with PMMA, radiographic outcomes with the CSC cement revealed complications including vacuum disc formation, cement leakage, and bone non-union. Investigators reported rapid CSC resorption as a potential cause of the complications [37] . The problem of lack of permanent structural support after augmentation was seen during patient follow-up [35] . To solve this issue, CSC was combined with CPC which has slower degradation rate, but the rate of resorption was still too fast ( Figure 3 ) [38] .
Apatite CPCs have been generally used as bone grafts because of their osteoconductivity but their ability to enhance healing was limited in large bone defects due to insufficient degradation of the material itself. To address this problem, biphasic CPCs based on tricalcium phosphate have been developed, but additional in vivo studies are needed to evaluate their potentials [39] . Biphasic, triphasic, and multiphasic calcium orthophosphates have promising potential for reconstruction of bone defects [40] . An injectable triphasic, calcium-based implant material was recently developed and investigated in a setting of augmentation of proximal femur. The material hardens within 20 minutes, and it was demonstrated to lead to increased bone formation [41] .
Other developments include the introduction of an injectable macroporous CPC obtained by incorporating water-soluble mannitol as a porogen into CPC that can be adjusted to optimize CPC its injectability and its porosity and strength which can then be suitable to be used in various minimally invasive techniques [42] . Magnesium ammonium phosphate hexahydrate (struvite) implants with different porosities were tested with mechanical loading in sheep and was found to be useful for treating partial load-bearing defects [43] . A composite made of coprecipitating octacalcium phosphate and gelatin [44] discs were formed and implanted in large rat calvarial defects, which led to bone regeneration. The formed bone was oriented relative to the amount of octacalcium phosphate in the gel.
Bioactive glass materials have been recognized as a future alternative to bone cements owing to their excellent biocompatibility, bioactivity, mechanical properties, and osteoinductivity [45] . A recent study has introduced injectable bioactive glass bone cement with improved osteoinductivity, suitable mechanical properties, and degradability demonstrated in vivo. Compared to conventional cements made of PMMA or CP-based composite, the bioactive glass cement led to improved bone regeneration in critical-sized rabbit femoral condylar bone defects (Figure 3 ) [38] .
A randomized controlled trial of 256 patients examined the differences between traditional PMMA bone cement and a new, nonresorbable bioactive composite (Cortoss) with little to no exothermic reaction. This study showed no difference in complication rates, no evidence of adverse exothermic events with bone cement and no difference in the reduction of the patients' pain levels [46] . Although the randomized controlled trial demonstrated no significant difference between the two substances, Cortoss is however more prone to extravasation.
Research into developing new bioactive glass materials continues and recently a new family of calcium ortho-/pyrophosphate glasses has been developed as an injectable bone regenerating gel [47] .
Hydrogels
A scaffold was made by incorporating fibrin into alginate hydrogel and encapsulating human bone marrow-derived mesenchymal stem cells (MSCs) for injectable stem cell bone therapy. Microfibers were used for delivery and for protection of the MSCs during preparation and injection. After injection, the microfibers degraded and encapsulated cells were released allowing for cell migration and tissue regeneration. Robust bone regeneration and complete osseous bridging was seen in critical-size rat mandibular defects [48] . Injectable hydrogel encapsulating MSCs is thought to be promising for bone regeneration in dental, craniofacial, and orthopedic applications [48] . MSCs encapsulating alginate-fibrin microbeads were used to produce injectable matrices for bone tissue regeneration [49] . Injectable biodegradable alginate-based gel scaffolds integrating hydroxyapatite (HAp) and gelatin microspheres were also developed for drug delivery and tissue engineering [50] . Adding cells to such osteoconductive material containing hydrogels can enhance multifunctionality of the biomaterials further. Thus, a composite of nano-HAp and platelet-rich fibrin granules encapsulating MSC sheets was developed for bone regeneration in rabbit calvarial large bone defects, and it was found that this enhances bone regeneration [51] . Furthermore, an injectable thermo-responsive methylcellulose hydrogel containing CP nanoparticles was studied in vitro and in vivo, and the rate of bone regeneration was better as compared to the use of methylcellulose composite alone [52] . With all these advances, a new generation of viable injectable biomaterials should have better performance and reduced problems and risks of complications.
Microparticles
Injectable scaffolds incorporating silica nanopowder into chitosan-tripolyphosphate microparticles were produced and studied in vitro for bone regeneration [53] . Adding silica nanopowder to microparticles enhanced the growth and proliferation of osteoblasts. Recently, injectable nanoHApchitosan-gelatin microscaffolds were developed and injected into a rabbit model [54] . At multiple follow-up intervals, enhanced regeneration of knee subchondral bone lesions was noted, thereby introducing a potential new strategy for treating knee osteoarthritis [54] .
Conclusion
Considering the prevalence of spine problems, the development of new therapies for the treatment of VCFs is becoming increasingly important.
New injectable biomaterials, including osteoconductive bone cements, ceramic hydrogels such as bioactive glass materials, and multiphasic CPCs, hold great promises to enhance subchondral bone lesion regeneration, promote bone regeneration, reduce exothermic reactions, and suppress of bone resorption and represent possible clinical benefits.
